A post-hoc analysis of baseline plasma and tumor tissue samples collected from 198 patients with ALK+ NSCLC from the phase II study of lorlatinib showed that patients harboring ALK mutations experienced major benefits from lorlatinib with respect to patients without mutations in terms of the ORR (about 60% vs. 30%) and mPFS (7.3 vs. 5.5 months for the plasma group, 11 vs. 5.4 months for the tissue group), respectively [83]. This evidence concerns the gene ALK and non-small cell lung carcinoma.